Answers are grounded in this paper and cite their sources.
This editorial refers to ‘Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30 years’, by A.N. Koshy et al., doi: 10.1093/ehjqcco/qcaa009. Historically, patients with non-alcoholic cirrhosis were considered to have a low risk for cardiovascular dysfunction. This paradigm has markedly shifted in the last 15 years with increasing recognition of cardiovascular morbidity and mortality after liver transplantation (LT).1 This can be partly attributed to increased recognition of adverse cardiovascular outcomes as a result of better understanding of physiology of heart liver interactions. The increased age and survival of LT recipients in the current times is another contributing factor. In the accompanying paper, Koshy et al.2 report trends in mortality after LT, from 1985 to 2017, highlighting the burden of cardiovascular mortality after LT. Koshy et al. analysed data collected by the Australian and New Zealand Liver Transplant Registry over a 33-year period and included over 4000 patients in their analysis. They divided this period into three 11-year eras (era 1: 1985–95, era 2: 1996–2006, and era3: 2007–17), and evaluated incidence and predictors of early (within 30 days of LT) and late (> 30 days after LT) cardiovascular mortality. As expected, with improvement in overall transplant and perioperative therapies, 30-day all-cause mortality improved across all the eras. It was 10.8% in era 1, 5.2% in era 2, and 2.3% in era 3. Also, early and late cardiovascular mortality was much higher in era 1 compared to era 2 or 3. However, it is important to note that the risk of cardiovascular mortality did not change between era 2 and 3, after adjusting for age, sex, and aetiology of cirrhosis. In fact, early cardiovascular mortality measured as a proportion of all-cause mortality increased to 40% in era 3, compared with 30% in era 1 and 2. Moreover, the absolute 30-day all-cause mortality after LT in the contemporary era (2.3%) is higher than many other high-risk surgeries. In comparison, 30-day mortality after coronary artery bypass graft surgery or aortic valve replacement, as reported by Society of Thoracic Surgery in 2016 is 2.2%.3 Also, the early cardiovascular mortality reported by Koshy et al. is three times higher than other high-risk abdominal surgeries like Whipple procedure.4 This highlights the magnitude of the problem and the need for further research to improve cardiovascular outcomes after LT. Many studies have identified predictors and attempted to create risk scores for predicting cardiovascular morbidity and mortality after LT.5–7 Koshy et al. and other investigators have found that history of coronary artery disease is an independent risk factor for cardiovascular morbidity and mortality.2,6 However, current data have many important limitations largely arising from the retrospective nature of these studies. Although many of these registries are prospectively collected, various newly recognized predictors and outcomes were not included in these analyses. It is quite likely that certain cardiovascular adverse events are underreported after LT, since they are not actively looked for. For instance, echocardiograms are not routinely performed after LT. And hence patients without typical heart failure symptoms will not be captured in these databases. Various important predictors of adverse cardiovascular outcome are not routinely collected in transplant registries. This is especially true for cirrhotic cardiomyopathy. The term ‘cirrhotic cardiomyopathy’ was first defined at the world congress of gastroenterology in 2005.8 Proposed diagnostic criteria included reduced systolic reserve, diastolic dysfunction, and electrophysiological abnormalities. Since then, there has been overwhelming evidence showing that cirrhotic cardiomyopathy predisposes patients to heart failure after LT. Despite that, cirrhotic cardiomyopathy is not included in most transplant registries. This is largely due to challenges with diagnosing cirrhotic cardiomyopathy. Although various studies use diastolic dysfunction as the main criteria to diagnose cirrhotic cardiomyopathy, reduced systolic reserve is difficult to evaluate. The cirrhotic cardiomyopathy consortium statement from 2019 highlights the challenges with diagnosis of cirrhotic cardiomyopathy.9 They recommend that advanced echocardiographic modalities like tissue Doppler imaging and myocardial strain imaging may be helpful. Role of additional markers of myocardial dysfunction such as contractile reserve on stress imaging, cardiac magnetic resonance imaging, and submaximal exercise testing need further evaluation. Although history of coronary artery disease is a known risk factor for cardiovascular adverse events after LT, the best strategy to evaluate for coronary artery disease in cirrhosis is unclear. Commonly used non-invasive modalities like dobutamine stress echocardiogram or nuclear perfusion imaging poorly predict adverse outcomes after LT.10 Dobutamine stress echocardiography is commonly used, however, most patients with cirrhosis are on beta-blockers and hence have a lower likelihood of achieving maximum predicted heart rate, making the results difficult to interpret. This is consistent with American College of Cardiology and American Heart Association guidelines, which state that non-invasive stress testing has poor sensitivity and specificity in patients with cirrhosis.11 Hence, an optimal strategy for preoperative cardiac testing in LT candidates has yet to be determined. Cardiovascular events occurring late after LT are poorly studied. In Koshy et al.’s cohort, the median time to late cardiovascular death was 9 years after LT. Thus, there is ample time for institution of effective therapy and risk factor modification after LT, if patients at risk are identified early on. The prevalence of metabolic syndrome has been shown to be high among LT recipients. About 35% patients develop new-onset metabolic syndrome after LT, increasing their risk for cardiovascular events.12 Also, the choice of immunosuppressive regimen may have an impact on metabolic syndrome after LT.1 Identifying modifiable risk factors for late cardiovascular morbidity and its association with immunosuppressive drugs would help improve cardiovascular death many years after LT. In summary, Koshy et al. highlight the presence of substantial cardiovascular morbidity and mortality among LT recipients in the contemporary era, despite improvement in various other realms of transplant medicine. Future studies aimed at identifying modifiable risk factors and optimal treatment strategies are needed to address this. Also, better characterization of cirrhotic cardiomyopathy and coronary artery disease among LT candidates will help identify high-risk candidates. Conflict of interest: none declared. The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal – Quality of Care and Clinical Outcomes or of the European Society of Cardiology.
No takes yet. Share an insight, caveat, or question.
Abraham Sonny (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: